MindWalk Holdings Corp.

NASDAQ:HYFT

Biotechnology

Healthcare
$1.08 +0.33%

+$0.01 today

Market cap
$50.88M
Beta
0.82
P/E (TTM)
-8.1
EPS (TTM)
-$0.26
52W Low $0.82High $3.25

Volume 0.20M

Average 0.32M

HYFT Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

MindWalk Holdings Corp.NASDAQ: HYFT

Cost of Revenue · Q3 FY2026 · quarter ended Jan 2026

Cost of revenue declines year over year

Q3 FY2026 cost of revenue of CA$1.67M fell 41.7% year over year, behind the -18.9% change in trailing-twelve-month cost of revenue. Sequentially, it rose 14.0% from the prior quarter. Over 3 fiscal years it compounded at +9.4% a year.

Context

  • Cost of revenue amounted to 44.7% of revenue in FY2025, down 6.1 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -41.7% toward the trailing-twelve-month pace of -18.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJan 2026
CA$1.67M+14.0% QoQ
Last fiscal yearApr 2025
CA$10.97M-12.0% YoY
LTMJan 2026
CA$7.28M-18.9% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-41.7%——
1 year-12.0%——
3-year CAGR+9.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

CAD · from the income statement

Latest · FY2025
10.97M CAD
Year-over-year change
-12.0%
4-year CAGR
+14.5%

Cost of Revenue vs competitors

How HYFT compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -18.9% is the 4th highest of 6, against a peer median of +4.7%.
  • Cost of revenue amounts to 39.7% of revenue for HYFT, versus a peer median of 158.8%.
HYFT Competitors
Cost of Revenue for HYFT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$23.48M USD+4.7%-12.1%35.5%
ATYRaTyr Pharma, Inc.LTM Mar 2026$22.52M USD+84.2%-2.9%11854.7%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$7.28M CAD-18.9%+9.4%39.7%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$936K USD——23.8%
CLNNClene Inc.LTM Mar 2026$378K USD+410.8%+18.3%282.1%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$211K USD———
ALXOALX Oncology Holdings Inc.LTM Mar 2026$150K USD-31.8%——
BYSIBeyondSpring Inc.LTM Mar 2026$19K USD———
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$0 USD-100.0%——
Peer median (excluding HYFT) —+4.7%-2.9%158.8%

Competitors are the stored peer set for HYFT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Revenue17.91M19.36M20.67M24.52M24.52M
Cost of Revenue6.37M8.38M9.1M12.47M10.97M
Gross Profit11.54M10.98M11.56M12.05M13.55M
Gross Margin64.4%56.7%56.0%49.2%55.3%
Research & Development1.97M7.66M14.1M4.04M4.94M
Selling, General & Admin13.27M18.06M18.99M19.14M19.03M
Operating Expenses15.71M27.66M37.17M25.82M25.74M
Depreciation & Amortization3.71M3.77M6.69M5.74M5.12M
EBITDA(1.42M)(11.99M)(21.04M)(22.95M)(28.86M)
EBITDA Margin-7.9%-61.9%-101.8%-93.6%-117.7%
Operating Income(4.18M)(16.67M)(25.61M)(13.76M)(12.2M)
Operating Margin-23.3%-86.1%-123.9%-56.1%-49.7%
Interest Income265.01K279K122K23K0
Interest Expense602.37K85K30K19K9.91K
Other Income / Expenses(1.82M)825K(2.14M)(14.94M)(22.07M)
Income Before Tax(6M)(15.85M)(27.75M)(28.7M)(34.27M)
Pre-Tax Margin-33.5%-81.8%-134.3%-117.1%-139.8%
Income Tax Expense1.35M861K(1.19M)(2.59M)(4.03M)
Net Income(7.34M)(16.71M)(26.56M)(26.12M)(30.23M)
Net Margin-41.0%-86.3%-128.5%-106.5%-123.3%
EPS (Basic)(0.45)(0.87)(1.07)(1.03)(0.90)
EPS (Diluted)(0.45)(0.87)(1.07)(1.03)(0.90)
Weighted Avg Shares16.47M19.69M24.9M25.64M33.39M
Weighted Avg Shares (Diluted)16.47M19.69M24.9M25.64M33.39M

MindWalk Holdings Corp.

NASDAQ:HYFT

Intrinsic Alpha fair value

Locked

Current Price

$1.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.